Sandbox:Sara: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) No edit summary |
Sara Mohsin (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
{| class="wikitable" | {| class="wikitable" | ||
|+Treatment options for dermatofibrosarcoma protuberans | |+Treatment options for dermatofibrosarcoma protuberans | ||
!Treatment option | !style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Treatment option}} | ||
!Details | !style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Details}} | ||
|- | |- | ||
|'''[[Surgery]]''' | |style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''[[Surgery]]''' | ||
| | | | ||
*[[Mohs micrographic surgery]] | *[[Mohs micrographic surgery]] | ||
| Line 16: | Line 16: | ||
**3-[[Dimensional analysis|dimensional]] [[histological]] evaluation of margins (necessarily recommended in order to [[Prevention (medical)|prevent]] the [[tumor]] [[Recurrence plot|recurrence]]) | **3-[[Dimensional analysis|dimensional]] [[histological]] evaluation of margins (necessarily recommended in order to [[Prevention (medical)|prevent]] the [[tumor]] [[Recurrence plot|recurrence]]) | ||
|- | |- | ||
|[[Targeted therapy|'''Targeted therapy''']] | |style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[Targeted therapy|'''Targeted therapy''']] | ||
| | | | ||
* [[Imatinib]]-[[STI571]] ([[tyrosine kinase inhibitor]]) [[therapy]] (may be [[Effective method|effective]] in [[CD117]]- [[tumors]]) is the [[Gold standard (test)|gold standard]] [[Treatments|treatment]] of [[Recurrence plot|recurrent]] or [[inoperable]] [[tumor]] | * [[Imatinib]]-[[STI571]] ([[tyrosine kinase inhibitor]]) [[therapy]] (may be [[Effective method|effective]] in [[CD117]]- [[tumors]]) is the [[Gold standard (test)|gold standard]] [[Treatments|treatment]] of [[Recurrence plot|recurrent]] or [[inoperable]] [[tumor]] | ||
* As [[imatinib]] [[Inhibition|inhibits]] [[PDGFB]], may be [[Effective method|effective]] for [[tumors]] positive for the t(17;22) [[Translocations|translocation]] | * As [[imatinib]] [[Inhibition|inhibits]] [[PDGFB]], may be [[Effective method|effective]] for [[tumors]] positive for the t(17;22) [[Translocations|translocation]] | ||
|- | |- | ||
|'''[[Chemotherapy]]''' | |style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''[[Chemotherapy]]''' | ||
| | | | ||
* Less beneficial than [[targeted therapy]] | * Less beneficial than [[targeted therapy]] | ||
|- | |- | ||
|'''[[Radiotherapy]]''' | |style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''[[Radiotherapy]]''' | ||
| | | | ||
* May be required sometimes | * May be required sometimes | ||
Revision as of 16:56, 16 August 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
| Treatment option | Details |
|---|---|
| Surgery |
|
| Targeted therapy |
|
| Chemotherapy |
|
| Radiotherapy |
|
Reference
- ↑ Huis In 't Veld EA, van Houdt WJ (2019). "Reply to Follow-up after treatment of dermatofibrosarcoma protuberans". Cancer. doi:10.1002/cncr.32341. PMID 31251395.
- ↑ Loss L, Zeitouni NC (2005). "Management of scalp dermatofibrosarcoma protuberans". Dermatol Surg. 31 (11 Pt 1): 1428–33. PMID 16416612.
- ↑ Dawes KW, Hanke CW (1996). "Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins". Dermatol Surg. 22 (6): 530–4. PMID 8646467.
- ↑ Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM; et al. (2000). "Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution". Cancer. 88 (12): 2711–20. PMID 10870053.
- ↑ DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK (2004). "Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution". Cancer. 100 (5): 1008–16. doi:10.1002/cncr.20051. PMID 14983497.
- ↑ Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB (2004). "Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature". Cancer. 101 (1): 28–38. doi:10.1002/cncr.20316. PMID 15221986.